Luteinizing hormone-releasing hormone enhances T cell recovery following allogeneic bone marrow transplantation

Gabrielle L Goldberg, Christopher G King, Rebecca A Nejat, David Y Suh, Odette M Smith, Jamison C Bretz, Robert M Samstein, Jarrod Andrew Dudakov, Ann Patricia Chidgey, Selina Chen-Kiang, Richard Lennox Boyd, Marcel R M van den Brink

    Research output: Contribution to journalArticleResearchpeer-review

    50 Citations (Scopus)


    Posttransplant immunodeficiency, specifically a lack of T cell reconstitution, is a major complication of allogeneic bone marrow transplantation. This immunosuppression results in an increase in morbidity and mortality from infections and very likely contributes to relapse. In this study, we demonstrate that sex steroid ablation using leuprolide acetate, a luteinizing hormone-releasing hormone agonist (LHRHa), increases the number of lymphoid and myeloid progenitor cells in the bone marrow and developing thymocytes in the thymus. Although few differences are observed in the peripheral myeloid compartments, the enhanced thymic reconstitution following LHRHa treatment and allogeneic bone marrow transplantation leads to enhanced peripheral T cell recovery, predominantly in the naive T cell compartment. This results in an increase in T cell function in vivo and in vitro. Graft-versus-host-disease is not exacerbated by LHRHa treatment and graft-versus-tumor activity is maintained. Because LHRHa allows for reversible (and temporary) sex steroid ablation, has a strong safety profile, and has been clinically approved for diseases such as prostate and breast cancer, this drug treatment represents a novel therapeutic approach to reversal of thymic atrophy and enhancement of immunity following immunosuppression.
    Original languageEnglish
    Pages (from-to)5846 - 5854
    Number of pages9
    JournalJournal of Immunology
    Issue number9
    Publication statusPublished - 2009

    Cite this